{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:07:12Z","timestamp":1783922832226,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04925-6","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:27:17Z","timestamp":1783920437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The value of target-site physiologically-based pharmacokinetics for high-affinity small molecules: a mechanistic foundation for precision dosing in oncology and hematology"],"prefix":"10.1007","volume":"96","author":[{"given":"Suzanne","family":"van der Gaag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke H.","family":"Bartelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"8","key":"4925_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2174\/1871520621666210811105344","volume":"22","author":"D Karati","year":"2022","unstructured":"Karati D, Ramoo Mahadik K, Trivedi P, Kumar D (2022) Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy. Anticancer Agents Med Chem 22(8):1478\u20131495","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"4925_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11912-022-01345-6","volume":"25","author":"H Pourhassan","year":"2023","unstructured":"Pourhassan H, Douer D, Pullarkat V, Aldoss I (2023) Asparagiinase: How to Better Manage Toxicities in Adults. Curr Oncol Rep 25(1):51\u201361","journal-title":"Curr Oncol Rep"},{"key":"4925_CR3","doi-asserted-by":"crossref","unstructured":"Mahmood I (2021) Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies 21;10(2):20","DOI":"10.3390\/antib10020020"},{"issue":"6","key":"4925_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4062\/biomolther.2024.146","volume":"32","author":"SM Choi","year":"2024","unstructured":"Choi SM, Lee JH, Ko S, Hong SS, Jun HE (2024) Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies. Biomol Ther 32(6):708\u2013722","journal-title":"Biomol Ther"},{"issue":"1","key":"4925_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12885-021-07782-z","volume":"21","author":"J Fraisse","year":"2021","unstructured":"Fraisse J, Dinart D, Tosi D, Bellera C, Mollevi C (2021) Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer 21(1):60","journal-title":"BMC Cancer"},{"key":"4925_CR6","doi-asserted-by":"publisher","first-page":"1144056","DOI":"10.3389\/fonc.2023.1144056","volume":"13","author":"R Murphy","year":"2023","unstructured":"Murphy R, Halford S, Symeonides SN (2023) Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective. Front Oncol 13:1144056","journal-title":"Front Oncol"},{"issue":"3","key":"4925_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/cts.12448","volume":"10","author":"ML Rizk","year":"2017","unstructured":"Rizk ML, Zou L, Savic RM, Dooley KE (2017) Importance of Drug Pharmacokinetics at the Site of Action. Clin Transl Sci 10(3):133\u2013142","journal-title":"Clin Transl Sci"},{"issue":"2","key":"4925_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1128\/CMR.00092-12","volume":"26","author":"D Gonzalez","year":"2013","unstructured":"Gonzalez D, Schmidt S, Derendorf H (2013) Importance of Relating Efficacy Measures to Unbound Drug Concentration for Anti-Infective Agents. Clin Microbiol Rev 26(2):274\u2013288","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4925_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.1211","volume":"106","author":"IH Bartelink","year":"2018","unstructured":"Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y et al (2018) Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clin Pharmacol Ther 106(1):148\u2013163","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4925_CR10","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.1038\/s41598-017-13025-8","volume":"7","author":"Y Tsubata","year":"2017","unstructured":"Tsubata Y, Hayashi M, Tanino R, Aikawa H, Ohuchi M et al (2017) Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. Sci Rep 7(1):12622","journal-title":"Sci Rep"},{"issue":"4","key":"4925_CR11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/molecules27041310","volume":"27","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Lin W, Zhu L (2022) Targeted Drug Delivery for the Treatment of Blood Cancers. Molecules 27(4):1310","journal-title":"Molecules"},{"issue":"4","key":"4925_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrd.2018.26","volume":"17","author":"RAB Van Waterschoot","year":"2018","unstructured":"Van Waterschoot RAB et al (2018) Impact of target interactions on small-molecule drug disposition: an overlooked area. Nat Rev Drug Discov 17(4):299","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"4925_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2967\/jnumed.117.203505","volume":"59","author":"NJ Begum","year":"2018","unstructured":"Begum NJ et al (2018) The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides. J Nucl Med 59(6):929\u2013933","journal-title":"J Nucl Med"},{"issue":"1","key":"4925_CR14","doi-asserted-by":"publisher","first-page":"20041","DOI":"10.1038\/s41598-019-56603-8","volume":"9","author":"NJ Begum","year":"2019","unstructured":"Begum NJ et al (2019) The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model. Sci Rep 9(1):20041","journal-title":"Sci Rep"},{"issue":"2","key":"4925_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/mp.14622","volume":"48","author":"D Hardiansyah","year":"2021","unstructured":"Hardiansyah D et al (2021) Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic model. Med Phys 48(2):556\u2013568","journal-title":"Med Phys"},{"issue":"4","key":"4925_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/diagnostics12040883","volume":"12","author":"EA Van de Stadt","year":"2022","unstructured":"Van de Stadt EA et al (2022) Relationship between Biodistribution and Tracer Kinetics of 11C-erlotinib, 18F-afatinib and 11C-osimertinib and Image Quality Evaluation Using Pharmacokintic\/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients. Diagnostics 12(4):883","journal-title":"Diagnostics"},{"issue":"7","key":"4925_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/ph15070796","volume":"15","author":"IH Bartelink","year":"2022","unstructured":"Bartelink IH et al (2022) Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. Pharmaceuticals 15(7):796","journal-title":"Pharmaceuticals"},{"key":"4925_CR18","doi-asserted-by":"crossref","unstructured":"Oh JH et al (2025) Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patients. Neuro Oncol. 2026 Jan 1;28(1):130-142","DOI":"10.1093\/neuonc\/noaf204"},{"issue":"3","key":"4925_CR19","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1021\/acs.analchem.1c04579","volume":"94","author":"N Strittmatter","year":"2022","unstructured":"Strittmatter N et al (2022) Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Anal Chem 94(3):1795\u20131803","journal-title":"Anal Chem"},{"key":"4925_CR20","doi-asserted-by":"publisher","first-page":"37027","DOI":"10.1038\/srep37027","volume":"6","author":"S Giordano","year":"2016","unstructured":"Giordano S et al (2016) 3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors. Sci Rep 6:37027","journal-title":"Sci Rep"},{"issue":"8","key":"4925_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.7150\/ijbs.41395","volume":"16","author":"L Morosi","year":"2020","unstructured":"Morosi L et al (2020) Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. Int J Biol Sci 16(8):1363\u20131375","journal-title":"Int J Biol Sci"},{"issue":"10","key":"4925_CR22","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2967\/jnumed.123.265738","volume":"64","author":"SAM Van Lith","year":"2023","unstructured":"Van Lith SAM et al (2023) PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study. J Nucl Med 64(10):1526\u20131531","journal-title":"J Nucl Med"},{"issue":"7","key":"4925_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jprot.2011.03.019","volume":"74","author":"G Marko-Varga","year":"2011","unstructured":"Marko-Varga G et al (2011) Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J Proteom 74(7):982\u2013992","journal-title":"J Proteom"},{"issue":"1","key":"4925_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13058-017-0896-4","volume":"19","author":"IH Bartelink","year":"2017","unstructured":"Bartelink IH et al (2017) Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res 19(1):107","journal-title":"Breast Cancer Res"},{"key":"4925_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.canlet.2021.10.012","volume":"524","author":"TNJ Del Flores-T\u00e9llez","year":"2022","unstructured":"Del Flores-T\u00e9llez TNJ, Baena E (2022) Experimental challenges to modeling prostate cancer heterogeneity. Cancer Lett 524:194\u2013205","journal-title":"Cancer Lett"},{"key":"4925_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","volume":"18","author":"C Cilliers","year":"2016","unstructured":"Cilliers C et al (2016) Multiscale modeling of antibody-drug conjugates: Connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS 18:1117\u20131130","journal-title":"AAPS"},{"key":"4925_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.12688\/f1000research.7210.1","volume":"5","author":"L Gay","year":"2016","unstructured":"Gay L, Baker AM, Graham TA (2016) Tumour cell heterogeneity. F1000Res 5:238","journal-title":"F1000Res"},{"issue":"4","key":"4925_CR28","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.7150\/thno.38625","volume":"10","author":"JS de Maar","year":"2020","unstructured":"de Maar JS et al (2020) Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment. Theranostics 10(4):1884\u20131909","journal-title":"Theranostics"},{"issue":"3","key":"4925_CR29","doi-asserted-by":"publisher","first-page":"e1004142","DOI":"10.1371\/journal.pcbi.1004142","volume":"11","author":"F Fu","year":"2015","unstructured":"Fu F, Nowak MA, Bobhoeffer S (2015) Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy. PLoS Comput Biol 11(3):e1004142","journal-title":"PLoS Comput Biol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04925-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:27:18Z","timestamp":1783920438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04925-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4925"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04925-6","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"74"}}